You are viewing the site in preview mode

Skip to main content

Articles

Page 2 of 7

  1. CD19 CAR T-cell therapy is a novel anti-cancer treatment that has produced remarkable responses in relapsed or refractory B-cell hematological malignancies. Cytokine Release Syndrome (CRS) is a dysregulated im...

    Authors: Andres E. Daryanani, Muhannad A. Abbasi, Maria F. Gomez Ardila, Eduardo Tellez-Garcia, Juan M. Garzon-Dangond, Yi Lin, Jonas Paludo, Joerg Herrmann, Stephen M. Ansell, Allison C. Rosenthal and Hector R. Villarraga
    Citation: Cardio-Oncology 2024 10:91
    Content type: Research Published on:

  2. Cancer patients are known to be associated with increased risk of cardiovascular disease. However, no studies have examined the differential impact of hematologic malignancies (HMs) and solid tumors (STs) on c...

    Authors: Michael H. Udin, Sunitha Shyam Sunder, Sarmila Nepali, Sharma Kattel, Amr Abdelradi, Scott T. Doyle, Ciprian N. Ionita, Qian Liu, Umesh C. Sharma and Saraswati Pokharel
    Citation: Cardio-Oncology 2024 10:90
    Content type: Research Published on:

  3. Breast cancer survivors face a higher risk of cardiovascular disease (CVD) compared to non-breast cancer patients, yet contemporary data on CVD-related mortality within this group remains scarce.

    Authors: Yong-Hao Yeo, Boon-Jian San, Jia-Yi Tan, Min-Choon Tan, Teodora Donisan, Justin Z. Lee, Laura M. Franey and Salim S. Hayek
    Citation: Cardio-Oncology 2024 10:89
    Content type: Research Published on:

  4. Despite advanced in targeted cancer therapies, anthracyclines remain essential in treating various malignancies, albeit with risks of cancer therapy-related cardiac dysfunction (CTRCD). Out of the myriad of mi...

    Authors: John Lee, Sean Tan and Satish Ramkumar
    Citation: Cardio-Oncology 2024 10:88
    Content type: Correspondence Published on:

  5. Androgen deprivation therapy (ADT), a key element of prostate cancer treatment, is associated with increased risk for cardiovascular morbidity and mortality. The underlying mechanisms include adverse metabolic...

    Authors: Antonia Beitzen-Heineke, David R. Wise and Jeffrey S. Berger
    Citation: Cardio-Oncology 2024 10:87
    Content type: Review Published on:

  6. Chemotherapy is one of the routine treatment for preventing rapid growth of the tumor cells. However, chemotherapeutic agents, especially doxorubicin cause damages to the normal cells especially cardiomyocytes...

    Authors: Golnaz Kheradkhah, Mohammad Sheibani, Tina Kianfar, Zahra Toreyhi and Yaser Azizi
    Citation: Cardio-Oncology 2024 10:86
    Content type: Review Published on:

  7. Global longitudinal strain (GLS) has been used to identify patients at risk for cancer-therapy related cardiac dysfunction (CTRCD). However, there is limited data on the effectiveness of initiating cardioprote...

    Authors: Fei Fei Gong, Eli Grunblatt, Woo Bin Voss, Vibhav Rangarajan, Sasan Raissi, Kimberly Chow, Lua Jafari, Nikita P. Patel, Inga Vaitenas, Milica Marion, Haydee Ramirez, Manyun Zhao, Adin-Christian Andrei, Abigail S. Baldridge, Gillian Murtagh, Kameswari Maganti…
    Citation: Cardio-Oncology 2024 10:85
    Content type: Research Published on:

  8. Clonal hematopoiesis of indeterminate potential (CHIP) has been shown to increase all-cause mortality and risk of cardiomyopathy in patients with solid malignancies. CHIP has also been shown to increase T cell...

    Authors: Rachel Jaber Chehayeb, Jaiveer Singh, Carlos Matute-Martinez, Nathan W. Chen, Ana Ferrigno Guajardo, Derrick Lin, Ritujith Jayakrishnan, Anthos Christofides, Etienne Leveille, Yunju Im, Giulia Biancon, Jennifer VanOudenhove, Eiman Ibrahim, Anastasias Ardasheva, Alokkumar Jha, John Hwa…
    Citation: Cardio-Oncology 2024 10:84
    Content type: Research Published on:

  9. Budd–Chiari syndrome is a rare and severe vascular liver disease. We presented patient with fulminant liver failure secondary to leiomyosarcoma of the IVC and thrombosis.

    Authors: Maciej Wiewiora, Hanna Wiewiora, Ewa Chmielik, Michal Jarzab, Michael Grynkiewicz and Marcin Kubeczko
    Citation: Cardio-Oncology 2024 10:83
    Content type: Case Report Published on:

  10. The advent of immune checkpoint inhibitors (ICIs) has significantly improved cancer treatment. With the increasing use of ICIs, ICI-related myocarditis has been recognized. However, an evidence-based therapeut...

    Authors: Ryo Izumi, Toru Hashimoto, Hiroshi Kisanuki, Kei Ikuta, Wataru Otsuru, Soshun Asakawa, Shoei Yamamoto, Kayo Misumi, Takeo Fujino, Keisuke Shinohara, Shouji Matsushima, Kazuya Hosokawa, Shunsuke Katsuki, Taro Mori, Mikiko Hashisako, Yuki Tateishi…
    Citation: Cardio-Oncology 2024 10:82
    Content type: Case Report Published on:

  11. Cardiac arrhythmia has been reported as a significant complication of thoracic radiotherapy. Both bradyarrhythmias and tachyarrhythmias have been reported, highlighting the arrhythmia-modulating potential of r...

    Authors: Markus B. Heckmann, Jan P. Münster, Daniel Finke, Hauke Hund, Fabian Schunn, Jürgen Debus, Christine Mages, Norbert Frey, Ann-Kathrin Rahm and Lorenz H. Lehmann
    Citation: Cardio-Oncology 2024 10:81
    Content type: Research Published on:

  12. Patients with non-small cell lung cancer (NSCLC) undergoing thoracic radiation are at high cardiovascular risk. Semiquantitative assessment of coronary artery calcification (CAC) on baseline planning non-gated...

    Authors: Matthew Lui, Noah Kim, Raja Zaghlol, Pouya Joolharzadeh, Elena Deych, Clifford Robinson, Shahed Badiyan, Pamela K. Woodard and Joshua D. Mitchell
    Citation: Cardio-Oncology 2024 10:80
    Content type: Research Published on:

  13. Venous thromboembolic events (VTE) are often diagnosed in ALK-positive lung cancer although it has not been demonstrated how their co-occurrence affects patients' survival.

    Authors: Magdalena Zaborowska-Szmit, Sebastian Szmit, Marta Olszyna-Serementa, Katarzyna Zajda, Anna Janowicz-Żebrowska, Piotr Jaśkiewicz, Dariusz M. Kowalski and Maciej Krzakowski
    Citation: Cardio-Oncology 2024 10:79
    Content type: Research Published on:

  14. This study aimed to increase the index of suspicion for transthyretin amyloidosis (ATTR) among cardiologists leading to increased screening for amyloidosis.

    Authors: Jessica Ammon, John Alexander, Woodson Petit-Frere, Deya Alkhatib, Aranyak Rawal, Grace Newman, Oguz Akbiligic, Brian Borkowski, John Jefferies and Isaac B. Rhea
    Citation: Cardio-Oncology 2024 10:78
    Content type: Research Published on:

  16. The mitral annular plane systolic excursion (MAPSE) is used to analyze the left ventricle longitudinal function. However, the accuracy of MAPSE in diagnosing oncological populations is unclear. In this study, ...

    Authors: Luís Fábio Barbosa Botelho, Marcelo Dantas Tavares de Melo, André Luiz Cerqueira de Almeida and Vera Maria Cury Salemi
    Citation: Cardio-Oncology 2024 10:76
    Content type: Research Published on:

  17. Venetoclax is a promising drug for patients with acute myeloid leukemia (AML) ineligible for anthracycline-based treatments. In rats, venetoclax is reported to cause myocardial injury. Our objectives were to r...

    Authors: Takeshi Onoue, Andrew H. Matthews, Azin Vakilpour, Yu Kang, Bénédicte Lefebvre, Amanda M. Smith, Shannon R. McCurdy, Michael G. Fradley, Joseph Carver, Jesse Chittams and Marielle Scherrer-Crosbie
    Citation: Cardio-Oncology 2024 10:75
    Content type: Correspondence Published on:

  18. Anthracyclines are essential in pediatric cancer treatment, but patients are at risk cancer therapy-related cardiac dysfunction (CTRCD). Standardized definitions by the International Cardio-Oncology Society (I...

    Authors: Xander Jacquemyn, Bhargava K. Chinni, Benjamin T. Barnes, Sruti Rao, Shelby Kutty and Cedric Manlhiot
    Citation: Cardio-Oncology 2024 10:74
    Content type: Research Published on:

  19. There have been several reports showing that heart-related deaths are common in long-term survivors of esophageal cancer after radiation therapy; however, radiotherapy technology is evolving year by year. This...

    Authors: Yuta Sato, Rei Umezawa, Takaya Yamamoto, Noriyoshi Takahashi, Yu Suzuki, Keita Kishida, So Omata, Hinako Harada, Yasuhiro Seki, Nanae Chiba, Shinsaku Okuda and Keiichi Jingu
    Citation: Cardio-Oncology 2024 10:73
    Content type: Research Published on:

  20. The association between cardiovascular disease and carcinogenesis is bidirectional and well-established. Furthermore, cancer treatment improves overall patient survival, potentially at the cost of incremental ...

    Authors: Saifei Liu, John D. Horowitz, Bogda Koczwara, Aaron L. Sverdlov, Natalie Packer and Robyn A. Clark
    Citation: Cardio-Oncology 2024 10:72
    Content type: Research Published on:

  21. Cancer survivors (CS) comprise a particularly high-risk group for both de-novo and recurrent malignancies after solid organ transplantation.

    Authors: Gal Rubinstein, Benjamin Izar, Diana E. McDonnell, Andrea Fernandez Valledor, Justin A. Fried, Kevin Clerkin, Edward F. Lin, Dor Lotan, Farhana Latif, Gabriel Sayer, Nir Uriel and Jayant K. Raikhelkar
    Citation: Cardio-Oncology 2024 10:71
    Content type: Case Report Published on:

  22. Trabectedin (Tbt) is an alkylating agent prescribed for soft tissue sarcomas after treatment failure of first line agents. While cardiomyopathy can occur with Tbt treatment after anthracycline exposure, Tbt-in...

    Authors: Annie J. Tsay, Mohan Satish, Elizabeth Corley, Ashley Ezema, Neisha DeJesus, Stephen Wisely, Eileen McAleer, Chen Zhang, Su Yuan, Edwin Homan, Jennifer E. Liu, Jonathan W. Weinsaft, Sandra D’Angelo, Stephanie A. Feldman and Angel T. Chan
    Citation: Cardio-Oncology 2024 10:70
    Content type: Case Report Published on:

  23. Cancer patients’ vulnerability to QT prolongation contradicts certain anti-cancer drug usage. Until now, the QT prolongation’s impact on CV mortality in cancer patients remains unclear, potentially biasing the...

    Authors: Cheng-Han Chan, Chih-Min Liu, Pei-Fen Chen, Li-Lien Liao, I-Chien Wu and Yu-Feng Hu
    Citation: Cardio-Oncology 2024 10:69
    Content type: Research Published on:

  24. While trastuzumab has been shown to improve disease-free and overall survival in patients with HER2-positive breast cancer, it may also cause trastuzumab-induced cardiotoxicity (TIC). Although racial and ethni...

    Authors: Anna Vaynrub, Leila Mishalani, Jayant Raikhelkar and Katherine D. Crew
    Citation: Cardio-Oncology 2024 10:68
    Content type: Research Published on:

  26. Despite routine echocardiographic surveillance for childhood cancer survivors, the ability to predict cardiomyopathy risk in individual patients is limited. We explored the feasibility and optimal processes fo...

    Authors: Lindsay A. Edwards, Christina Yang, Surbhi Sharma, Zih-Hua Chen, Lahari Gorantla, Sanika A. Joshi, Nicolas J. Longhi, Nahom Worku, Jamie S. Yang, Brandy Martinez Di Pietro, Saro Armenian, Aarti Bhat, William Border, Sujatha Buddhe, Nancy Blythe, Kayla Stratton…
    Citation: Cardio-Oncology 2024 10:66
    Content type: Research Published on:

    The Editorial to this article has been published in Cardio-Oncology 2024 10:77

  27. Doxorubicin (DOX) is used for breast cancer and lymphoma, but can cause cardiotoxicity, arterial stiffness, and endothelial dysfunction. We recently reported SERPINA3N as biomarker of cardiovascular toxicity i...

    Authors: Dustin N. Krüger, Matthias Bosman, Emeline M. Van Craenenbroeck, Guido R. Y. De Meyer, Constantijn Franssen and Pieter-Jan Guns
    Citation: Cardio-Oncology 2024 10:65
    Content type: Research Published on:

  28. The presence and burden of coronary artery calcium (CAC) is a strong predictor of cardiovascular events. Current guidelines of the European Society of Cardiology (ESC) for cardio-oncology do not recommend the ...

    Authors: Anna Borowiec, Patrycja Ozdowska, Magdalena Rosinska, Agnieszka Maria Zebrowska, Agnieszka Jagiello-Gruszfeld, Sławomir Jasek, Joanna Waniewska, Beata Kotowicz, Hanna Kosela-Paterczyk, Elzbieta Lampka, Katarzyna Pogoda, Andrzej Cieszanowski, Zbigniew Nowecki and Jan Walewski
    Citation: Cardio-Oncology 2024 10:64
    Content type: Research Published on:

  29. Heart failure (HF) in patients with cancer is associated with high morbidity and mortality. The success of cancer therapy has resulted in an exponential rise in the population of cancer survivors, however card...

    Authors: Michelle Bloom, Jose A. Alvarez-Cardona, Sarju Ganatra, Ana Barac, Iskra Pusic, Daniel Lenihan and Susan Dent
    Citation: Cardio-Oncology 2024 10:63
    Content type: Review Published on:

  30. Preliminary research reveals that many nurses feel inadequate and possess limited knowledge when it comes to managing cardiotoxicity, underscoring the necessity for educational programs to enhance nursing skil...

    Authors: Jeff Kolbus, Mopelola T. Adeola, Janelle M. Tipton and Caitlin E. D. Luebcke
    Citation: Cardio-Oncology 2024 10:62
    Content type: Research Published on:

  31. Clinical outcomes for TAVR in cancer survivors with prior chest radiation therapy (C-XRT) who develop symptomatic aortic-valve stenosis are not adequately assessed in major clinical trials leading to conflicti...

    Authors: Farah Yasmin, Abdul Moeed, Muhammad Tanveer Alam, Vikash Virwani, Yumna Khabir, Asim Shaikh, Apurva V. Vyas and M. Chadi Alraies
    Citation: Cardio-Oncology 2024 10:61
    Content type: Review Published on:

  32. Cancer therapy is considered to cause accelerated ischemia. Ankle-Brachial Index (ABI) measurement is an inexpensive, simple, available test for the early diagnosis of peripheral artery disease (PAD); however,...

    Authors: Netanel Golan, Rafael Y. Brzezinski, Moaad Slieman, Shafik Khoury, Ofer Havakuk, Yan Topilsky, Shmuel Banai and Michal Laufer-Perl
    Citation: Cardio-Oncology 2024 10:60
    Content type: Research Published on:

  33. Immune Checkpoint Inhibitors (ICIs) have revolutionized cancer therapy. This study examines the cardiovascular risks of ICIs compared to non-ICI therapies.

    Authors: Jian-Rong Peng, Jason Chia-Hsun Hsieh, Chih-Hao Chang, Chi Chuang, Yu-Ching Wang, Tzu-Yang Chen, Hung-Chi Su and Hsin-Fu Lee
    Citation: Cardio-Oncology 2024 10:59
    Content type: Research Published on:

  34. Anthracycline-based chemotherapy represents a cornerstone treatment for a number of common cancers, including breast cancer, lymphoma, and sarcoma. However, anthracycline-induced cardiotoxicity remains a signi...

    Authors: Andrés J. Daniele, Vanesa Gregorietti, Diego Costa and Teresa López – Fernández
    Citation: Cardio-Oncology 2024 10:58
    Content type: Research Published on:

  35. Doxorubicin (DOX) has been widely used in the treatment of breast cancer, but it is directly associated with late-onset cardiovascular disease (CVD). Whether anthropometric, food intake or other risk factors t...

    Authors: Karini Merolillo, Maria Inês González Solari, Tayani Palma Cohen, Andreas Lutz, Patricia de Carvalho, Fabio Cañellas, Diogo Rech, Otávio de Carvalho, Alice Zelmanowicz, Alexandre Machado Lehnen, Nance Nardi and Natalia Motta Leguisamo
    Citation: Cardio-Oncology 2024 10:57
    Content type: Research Published on:

  36. Cardiovascular toxicity represents a significant adverse consequence of cancer therapies, yet there remains a paucity of effective biomarkers for its timely monitoring and diagnosis. To give a first evidence a...

    Authors: Xiaohe Hao, Zhenyu Zhang, Jing Kong, Rufei Ma, Cuiping Mao, Xun Peng, Kun Ru, Lisheng Liu, Chuanxi Zhao, Xinkai Mo, Meijuan Cai, Xiangguo Yu and Qinghai Lin
    Citation: Cardio-Oncology 2024 10:56
    Content type: Research Published on:

  37. Patients with active cancer and aortic stenosis may be under-referred for valve interventions due to concerns over a prohibitive risk. However, whether active cancer impacts outcomes after transcatheter aortic...

    Authors: Nicole Felix, Alleh Nogueira, Pedro E. P. Carvalho, Thomaz Alexandre Costa, Lucas Tramujas, Giuliano Generoso, Stephanie Feldman, Philippe Garot and Maria do Carmo Andrade Duarte de Farias
    Citation: Cardio-Oncology 2024 10:55
    Content type: Research Published on:

  38. Radiation therapy (RT) for breast cancer (BC) can result in subtle cardiac dysfunction that can occur early after treatment. In 2022, the European Society of Cardiology (ESC) published the first guidelines in ...

    Authors: M. K. Honaryar, M. Locquet, R. Allodji, G. Jimenez, B. Pinel, O. Lairez, L. Panh, J. Camilleri, D. Broggio, J. Ferrières, F. De Vathaire and S. Jacob
    Citation: Cardio-Oncology 2024 10:54
    Content type: Research Published on:

  39. Immune checkpoint inhibitor (ICI) myocarditis is an uncommon but potentially fatal complication of immunotherapy. Cardiac imaging is essential to make timely diagnoses as there are critical downstream implicat...

    Authors: Jieli Tong, Nikolaos Vogiatzakis, Maria Sol Andres, Isabelle Senechal, Ahmed Badr, Sivatharshini Ramalingam, Stuart D. Rosen, Alexander R. Lyon and Muhummad Sohaib Nazir
    Citation: Cardio-Oncology 2024 10:53
    Content type: Correspondence Published on:

  40. Chimeric antigen receptor (CAR) T-cell therapy is a new revolutionary method for treating refractory or relapsed hematologic malignancies, CAR T-cell therapy has been associated with cytokine release syndrome ...

    Authors: Saba Maleki, Zahra Esmaeili, Niloofar Seighali, Arman Shafiee, Sara Montazeri Namin, Mohammad Amin Tofighi Zavareh, Sima Shamshiri Khamene, Izat Mohammadkhawajah, Michael Nanna, Azin Alizadeh-asl, Jennifer M.Kwan and Kaveh Hosseini
    Citation: Cardio-Oncology 2024 10:52
    Content type: Review Published on:

  41. The landscape of cancer survivorship is increasingly populated by individuals facing a spectrum of cardiometabolic risks, attributed to both their oncological history and treatment regimens. This manuscript sy...

    Authors: Arif Albulushi, Aisha Al Balushi, Muhhamed Shahzad, Ismail Al Bulushi and Hatim Al Lawati
    Citation: Cardio-Oncology 2024 10:51
    Content type: Review Published on:

  42. Fludarabine is a chemotherapeutic agent with lymphodepleting effects that is increasingly used as part of a conditioning regimen prior to allogeneic stem cell transplantation. Fludarabine is generally consider...

    Authors: Steve Kong, Sanjana Nagraj, Dennis L. Cooper, Kevin J. Ferrick and Lili Zhang
    Citation: Cardio-Oncology 2024 10:50
    Content type: Case Report Published on:

  43. Cardiac sarcoidosis though in itself, a rare entity, very rarely presents primarily with conduction abnormalities as the primary manifestation in the spectrum of presentations accounted by this chronic granulo...

    Authors: Jay Gohri, Harshvardhan Luthra, Khushboo Qureshi and Karnati Prudhveer Reddy
    Citation: Cardio-Oncology 2024 10:49
    Content type: Case Report Published on:

  44. Atrial fibrillation (AF) is more common in patients with malignancies than in general population. The pathophysiological processes include the pro-inflammatory condition and the exaggerated inflammatory reacti...

    Authors: Ermanno Nardi, Ciro Santoro, Maria Prastaro, Mario Enrico Canonico, Stefania Paolillo, Giuseppe Gargiulo, Paola Gargiulo, Antonio L. M. Parlati, Christian Basile, Luca Bardi, Mario Giuliano and Giovanni Esposito
    Citation: Cardio-Oncology 2024 10:48
    Content type: Review Published on:

  45. Within cardio-oncology, emerging epidemiologic studies have demonstrated a bi-directional relationship between heart failure (HF) and cancer. In the current study, we aimed to further explore this relationship...

    Authors: P. F. van den Berg, L. I. Yousif, G. Markousis-Mavrogenis, C. Shi, V. Bracun, J. Tromp, S. de Wit, Y. Appels, E. M. Screever, J. P. Aboumsallem, W. Ouwerkerk, D. J. van Veldhuisen, H. H. W. Silljé, A. A. Voors, R. A. de Boer and Wouter C. Meijers
    Citation: Cardio-Oncology 2024 10:47
    Content type: Research Published on:

  46. Participation in cardio-oncological rehabilitation is low, and the effects incline to decrease after the initial rehabilitation term. Home-based exercise has the potential to enhance involvement in cardio-onco...

    Authors: Katerina Chamradova, Ladislav Batalik, Petr Winnige, Filip Dosbaba, Martin Hartman, Katerina Batalikova, Andrea Janikova, Svatopluk Nehyba, Marian Felsoci, Garyfallia Pepera and Jing Jing Su
    Citation: Cardio-Oncology 2024 10:46
    Content type: Research Published on:

  47. Cardiac angiosarcoma is a very rare and aggressive primary cardiac tumor associated with poor prognosis. Diagnosis is often delayed due to non-specific symptoms, with most cases involving metastases at the tim...

    Authors: Noor Sharrack, Martine Parent, Christopher Lethaby, Ulrich Rosendahl, Alexander R Lyon, Maryum Farooq, Haqeel Jamil, John P. Greenwood, Sven Plein and Ananth Kidambi
    Citation: Cardio-Oncology 2024 10:45
    Content type: Case Report Published on:

  48. Trastuzumab treatment for salivary gland, gastric, and breast cancer commonly causes cancer treatment-related cardiac dysfunction (CTRCD). CTRCD incidence by sex has not been well studied.

    Authors: Yudai Tamura, Yuichi Tamura and Yuichiro Tada
    Citation: Cardio-Oncology 2024 10:44
    Content type: Research Published on:

  49. Cancer therapy-related cardiac dysfunction (CTRCD) is a dreaded complication of anthracycline therapy. CTRCD most frequently appears in patients with cardiovascular risk factors (CVR) or known cardiovascular d...

    Authors: Fabian Voß, Fabian Nienhaus, Saskia Pietrucha, Eugen Ruckhäberle, Tanja Fehm, Tobias Melz, Mareike Cramer, Sebastian M. Haberkorn, Ulrich Flögel, Ralf Westenfeld, Daniel Scheiber, Christian Jung, Malte Kelm, Amin Polzin and Florian Bönner
    Citation: Cardio-Oncology 2024 10:43
    Content type: Research Published on:

  50. The therapeutic landscape of chronic myeloid leukaemia (CML) has been transformed by tyrosine kinase inhibitors (TKI). Nilotinib, showed higher rates of major molecular response than imatinib, however associat...

    Authors: Fiona Fernando, Maria Sol Andres, Simone Claudiani, Nazanin Zounemat Kermani, Giulia Ceccarelli, Andrew J. Innes, Afzal Khan, Stuart D. Rosen, Jane F. Apperley, Alexander R. Lyon and Dragana Milojkovic
    Citation: Cardio-Oncology 2024 10:42
    Content type: Research Published on:
Submit manuscript

Follow

Annual Journal Metrics

  • Citation Impact 2023
    Journal Impact Factor: 3.2
    5-year Journal Impact Factor: N/A
    Source Normalized Impact per Paper (SNIP): 0.822
    SCImago Journal Rank (SJR): 0.958

    Speed 2024
    Submission to first editorial decision (median days): 13
    Submission to acceptance (median days): 100

    Usage 2024
    Downloads: 253,129
    Altmetric mentions: 271

Institutional membership

Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).

Funding your APC

​​​​​​​Open access funding and policy support by SpringerOpen​​

​​​​We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here. 

Cardio-Oncology

ISSN: 2057-3804

Contact us